Search results for "Cooking"

showing 10 items of 635 documents

MamaPred: A new and innovative approach to determine recurrence risk in HR+/HER2- early-stage breast cancer using HTG EdgeSeq technology.

2021

558 Background: Genomic platforms, such as Mammaprint (Agendia) (MP) and OncoType (Genomic Health) (OT), have been validated to determine the risk of relapse in therapeutic decision-making in early-stage hormone receptor positive (HR+), epidermal growth factor receptor 2 (HER2) negative breast cancer (BC). Discordances in risk allocation between these platforms affect up to 30% of patients. This study aims to develop the MamaPred test to improve the diagnostic performance of recurrence risk in HR+/HER2- early-stage BC. Methods: A total of 606 HR+/HER2- early-stage BC previously tested with OT [n = 287; Low Risk (LR) = 165, Intermediate Risk (IR) = 103 and High Risk (HR) = 19] and MP (n = 3…

OncologyCancer Researchmedicine.medical_specialtymedicine.diagnostic_testbusiness.industrymedicine.diseaseRecurrence riskBreast cancerOncologyMammaPrintInternal medicinemedicineRelapse riskStage (cooking)businessJournal of Clinical Oncology
researchProduct

Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis

2020

Background: Although the use of adjuvant chemotherapy (AC) appears to be increasing over the past few years, several clinical trials and previous meta-analyses failed to determine whether AC could improve clinical outcomes in uterine leiomyosarcoma (uLMS). The aim of this systematic review and meta-analysis was to compare AC (with or without radiotherapy) versus observation (obs) after primary surgery in early stage uLMS. Materials and Methods: Randomized controlled (RCTs) and non-randomized studies (NRSs) were retrieved. Outcomes of interest were as follows: distant recurrence rate, locoregional recurrence rate and overall recurrence rate. Results about distant recurrence rate, locoregiona…

OncologyCancer Researchmedicine.medical_specialtyuterine sarcomamedicine.medical_treatmentchemotherapylcsh:RC254-282meta-analysiArticleNOuterine leiomyosarcoma03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdjuvant therapy030212 general & internal medicineStage (cooking)meta-analysis uterine leiomyosarcoma uterine sarcoma adjuvant therapy chemotherapyUterine sarcomabusiness.industryadjuvant therapyOdds ratiomedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensConfidence intervalClinical trialRadiation therapymeta-analysisadjuvant therapy chemotherapyOncology030220 oncology & carcinogenesisMeta-analysisAdjuvant therapy Uterine sarcoma Uterine leiomyosarcoma Meta-analysis ChemotherapybusinessCancers
researchProduct

Carcinoembryonic Antigen as a Monitor in Breast Cancer

1981

: Carcinoembryonic antigen (CEA) levels were serially determined in 125 patients with breast cancer in order to study the diagnostic and prognostic use of serum CEA levels before and/or after surgery and during treatment with hormonal and chemotherapy. Serum CEA levels were elevated in 15.5% of nonmetastatic patients. Carcinoembryonic antigen increased according to stage (TNM classification); and a direct relationship between positive CEA levels and subsequent recurrence was found. After a three-year postoperative interval a 50% survival rate was exhibited in CEA-positive patients vs an 88% survival rate in those patients found to be CEA negative. There is a definite correlation between the…

OncologyChemotherapymedicine.medical_specialtyendocrine system diseasesResponse to therapybiologybusiness.industrymedicine.medical_treatmentmedicine.diseasedigestive system diseasesBreast cancerCarcinoembryonic antigenInternal medicinemedicinebiology.proteinStage (cooking)businessneoplasmsAdjuvantSurvival rateHormoneAmerican Journal of Reproductive Immunology
researchProduct

“Unexpectedly high survival rate in very poor prognosis stage III B breast cancer patients receiving cisplatin-based primary chemotherapy. A multicen…

2004

605 Background: Primary chemotherapy, as part of multimodality treatment, has become the standard of care for locally advanced breast cancer (LABC) to increase DFS, OS and conservative surgery. Stage III B is renowned as the worst of LABC, and despite appropriate therapy the majority of patients (pts) will experience distant metastases and death within 2–3 years. The optimal regimen and schedule of primary chemotherapy is uncertain. Aim of our study was to verify the efficacy of an original cisplatin-based regimen (PEV) in terms of response and survival. Methods: Between 1996 and 2001 72 consecutive III B pts were treated with primary chemotherapy: Cisplatin 50 mg/m2, Epirubicin 100 mg/m2, …

OncologyCisplatinCancer Researchmedicine.medical_specialtybiologybusiness.industrymedicine.medical_treatmentVinorelbinemedicine.diseaseRegimenBreast cancerOncologyKi-67Internal medicinemedicinebiology.proteinStage (cooking)skin and connective tissue diseasesbusinessAdjuvantmedicine.drugEpirubicin
researchProduct

Perfil genómico del neuroblastoma de alto riesgo mediante hibridación genómica comparada

2006

El neuroblastoma presenta alteraciones genéticas que predicen su evolución clínica. Ganancias cromosómicas completas están asociadas a estadios clínicos no avanzados y evolución favorable, mientras que pérdidas de 1p, ganancia de 17q y amplificación del gen MYCN (MNA) son indicativas de estadios clínicos avanzados y pronóstico desfavorable. Son neuroblastomas de alto riesgo (NB-HR) los presentes en niños mayores de un año: estadio 4 o MNA en cualquier estadio de enfermedad, excluyendo estadio 1. El pronóstico de estos enfermos es malo, incluso con tratamientos agresivos. Sólo MNA confiere valor pronóstico negativo. Se remitieron al Centro de Referencia Nacional del neuroblastoma 60 casos de…

OncologyComparative genomic hybridizationmedicine.medical_specialtyBiological studiesmedicine.diagnostic_testbusiness.industryFluorescence in situ hybridizationClinical courseIn situ hybridizationmedicine.diseasePediatricsRJ1-570NeuroblastomaInternal medicineNeuroblastomaMYCNPediatrics Perinatology and Child Healthmedicine1p DeletionStage (cooking)businessFluorescence in situ hybridizationComparative genomic hybridizationAnales de Pediatría
researchProduct

P-309 Correlation between baseline CEA levels and TNM stage at presentation in colorectal cancers in an Indian population

2020

OncologyCorrelationmedicine.medical_specialtyOncologybusiness.industryInternal medicinemedicineIndian populationHematologyStage (cooking)Presentation (obstetrics)businessBaseline (configuration management)Annals of Oncology
researchProduct

Prognostic value of the immunohistochemical detection of epithelial-mesenchymal transition biomarkers in oral epithelial dysplasia : a systematic rev…

2019

Background Oral potentially malignant disorders (OPMDs) comprise a range of clinical-pathological alterations that are frequently characterized as architectural and cytological derangements upon histological analysis. Epithelial-mesenchymal transition (EMT) has been proposed as a critical mechanism for the acquisition of the malignant phenotype in neoplastic epithelial processes. This study aims to systematically review the current findings on the immunohistochemical expression of epithelial-mesenchymal transition markers in oral potentially malignant disorders and to evaluate their possible application as biomarkers associated with the progression of oral epithelial dysplasias. Material an…

OncologyEpithelial dysplasiamedicine.medical_specialtyEpithelial-Mesenchymal TransitionReviewCochrane LibraryInternal medicineBiomarkers TumorMedicineEpithelial–mesenchymal transitionStage (cooking)General DentistryMalignant phenotypeOral Medicine and Pathologybusiness.industryMechanism (biology)Prognosis:CIENCIAS MÉDICAS [UNESCO]Epitheliummedicine.anatomical_structureOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASImmunohistochemistrySurgerybusinessBiomarkers
researchProduct

Baseline Metabolic Tumor Volume Predicts Outcome in High–Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies

2016

Purpose Identifying patients at high risk of progression and early death among those with high-tumor-burden follicular lymphoma (FL) is unsatisfactory with current prognostic models. This study aimed to determine the prognostic impact of the total metabolic tumor volume (TMTV) measured at baseline with [18F]fluorodeoxyglucose/positron emission tomography-computed tomography ([18F]FDG/PET-CT) scans and its added value to these models. Patients and Methods A pooled analysis was performed by using patient data and centrally reviewed baseline PET-CT scans for 185 patients with FL who were receiving immunochemotherapy within three prospective trials. TMTV was computed by using the 41% maximum st…

OncologyFluorodeoxyglucoseCancer Researchmedicine.medical_specialtybusiness.industryFollicular lymphomaStandardized uptake valueMetabolic tumor volumemedicine.disease030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinePooled analysisInternational Prognostic IndexOncology030220 oncology & carcinogenesisInternal medicineMedicinePositron emissionStage (cooking)businessNuclear medicinemedicine.drugJournal of Clinical Oncology
researchProduct

2021

This retrospective population-based study examined the impact of age and comorbidity burden on multimodal management and survival from colorectal cancer (CRC). From 2000 to 2015, 1479 consecutive patients, who underwent surgical resection for CRC, were reviewed for age-adjusted Charlson comorbidity index (ACCI) including 19 well-defined weighted comorbidities. The impact of ACCI on multimodal management and survival was compared between low (score 0–2), intermediate (score 3) and high ACCI (score ≥ 4) groups. Changes in treatment from 2000 to 2015 were seen next to a major increase of laparoscopic surgery, increased use of adjuvant chemotherapy and an intensified treatment of metastatic dis…

OncologyLaparoscopic surgerymedicine.medical_specialtyeducation.field_of_studyColorectal cancerbusiness.industrymedicine.medical_treatmentPopulationGeneral Medicinemedicine.diseaseComorbidity3. Good healthRadiation therapy03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisInternal medicinemedicineCarcinoma030211 gastroenterology & hepatologyStage (cooking)MetastasectomyeducationbusinessJournal of Clinical Medicine
researchProduct

Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer

2018

Background: Serum levels of neutrophils, platelets, and lymphocytes have been recognized as factors related to poor prognosis for many solid tumors, including bladder cancer (BC). Objective: To evaluate the prognostic role of the combination of the neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and lymphocyte/monocyte ratio (LMR) in patients with high-risk non–muscle-invasive urothelial BC (NIMBC). Design, setting, and participants: A total of 1151 NMIBC patients who underwent first transurethral resection of the bladder tumor (TURBT) at 13 academic institutions between January 1, 2002 and December 31, 2012 were included in this analysis. The median follow-up was 48 mo.…

OncologyMaleBladder cancer; Lymphocyte/monocyte ratio; Neutrophil/lymphocyte ratio; Platelet/lymphocyte ratio; Prognosis; Aged; Biomarkers Tumor; Blood Platelets; Carcinoma Transitional Cell; Cystectomy; Disease Progression; Female; Follow-Up Studies; Humans; Inflammation; Lymphocyte Count; Lymphocytes; Male; Monocytes; Neutrophils; Prognosis; Risk Factors; Urinary Bladder NeoplasmsNeutrophilsmedicine.medical_treatmentLymphocyte:Medicina Básica [Ciências Médicas]Prognosis.030232 urology & nephrologyMonocyteMonocytesSettore MED/24 - Urologia0302 clinical medicineRisk FactorsLymphocytesStage (cooking)Framingham Risk ScoreTumorNeutrophilBladder cancerPrognosis3. Good healthmedicine.anatomical_structureOncology030220 oncology & carcinogenesisNeutrophil/lymphocyte ratioCiências Médicas::Medicina BásicaDisease ProgressionLymphocyteFemalemedicine.symptomHumanBlood Plateletsmedicine.medical_specialtyPlatelet/lymphocyte ratioPrognosiUrologyInflammationCystectomyFollow-Up StudieCystectomy03 medical and health sciencesInternal medicinemedicineBiomarkers TumorHumansRadiology Nuclear Medicine and imagingLymphocyte CountAgedInflammationCarcinoma Transitional CellBladder cancerScience & Technologybusiness.industryProportional hazards modelRisk FactorCarcinomaLymphocyte/monocyte ratioImmunotherapymedicine.diseaseUrinary Bladder NeoplasmsBlood PlateletSurgeryTransitional CellbusinessBiomarkersFollow-Up Studies
researchProduct